Ataraxis AI Launches Ataraxis Breast CTX, the First Predictive AI Test Estimating Individualized Chemotherapy Benefit in Breast Cancer

Ataraxis AI announced Ataraxis Breast CTX, a new predictive capability within its Ataraxis Breast platform, designed to help estimate individualized chemotherapy benefit in breast cancer patients. With Ataraxis Breast CTX, the platform predicts patient-level outcomes under two treatment strategies, with and without adjuvant chemotherapy. This prediction is enabled by Ataraxis™ Tau, the company’s causal inference layer designed to account for treatment selection bias and confounding commonly present in retrospective and real-world datasets.